La cadena de opciones muestra datos clave de las opciones de acciones de Bluejay Diagnostics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Bluejay Diagnostics..

Bluejay Diagnostics (NASDAQ:BJDX) Bolsa, Cadena de Opciones

Bluejay Diagnostics

Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.

Levi Strauss

News

Pre-Market Outlook

Markets

Movers

AREB

BJDX

CHSN

CVRX

GLXG

GRFX

IPDN

IVDA

KNOP

KPTI

LEVI

PRSU

SOBR

STTK

SVRE

Levi sorprende al mercado con ganancias trimestrales mejores de lo esperado y una perspectiva 2025 que mantiene sin cambios.

Acciones de Levi Strauss suben un 10%; Aquí están 20 acciones que se mueven en el premercado de EE. UU.

Bluejay Diagnostics Inc

Supports plans to advance the RV01 program to first-in-human therapeutic basket study in solid tumour cancers
Data completes preclinical package for Investigational New Drug submission in mid-2025 with Phase 1 therapeutic study initiation expected in 4Q25
SYDNEY, Australia, June 02, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that preclinical data from studies with the Lu177-B7H3-monoclonal antibody RV01 demonstrated favourable biodistribution and showed that RV01 maintained high tumour uptake. In addition, the Fc region modifications of the monoclonal antibody (mAb) confirm a shorter half-life, compared to traditional mAbs. The shorter half-life and other Fc modifications have the potential to limit off-target exposure to the isotope and mitigate toxicities associated with traditional monoclonal antibody therapies.
RV01 is the Company's B7-H3-targeted radiopharmaceutical therapy designed with strong affinity for the 4Ig isoform of B7H3 that is highly expressed in tumours and not in healthy tissues, which is being developed in partnership with MD Anderson Cancer Center. The B7-H3 targeting monoclonal antibody (mAb) is designed to target various solid tumours that express the B7-H3 protein. High expression of this target is associated with a poor prognosis in many cancer types.
The new preclinical data corroborate conclusions from earlier preclinical mouse studies that identified a high-affinity antibody highly selective to the cancer-specific 4Ig isoform of the B7-H3 receptor, demonstrated complete regression of established solid tumours with treatment and showed promising evidence of immune system stimulation and the ability to confer immune memory.

RADX

Radiopharm Theranostics Says Preclinical Data From Studies With Lu177-B7H3-Monoclonal Antibody RV01 Demonstrates Favourable Biodistribution And Shows That RV01 Maintained High Tumour Uptake

Median overall survival data in first-line recurrent/metastatic (1L r/m) HNSCC remains durable at 30.0 months with additional follow-up of ~4.5 months beyond the initial abstract
HPV16-positive is the most rapidly increasing HNSCC in the US
VERSATILE-003 is the only ongoing Phase 3 clinical trial exclusively addressing 1L r/m HPV16-positive HNSCC
PRINCETON, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced publication of three Versamune&#xAE; HPV abstracts now available on the <a href="https://www.globenewswire.com/Tracker?data=ctgYUManXlUn9vXDbbZMFFqOJNNi_BKXlsy4YjYWF17J55joStlSKwaXSle3O56ubhP0psmiNueusD5j7EeKEz3qWOn54wF68KQCvF5_11ktrVp610uqjaxVY9otO537jxXOPBw4I1fUSbPzSa2eTQJTmWeP4HebVUhM-_Hj_iU=">2025 American Society of Clinical Oncology (ASCO) Annual Meeting</a> website. These abstracts summarize Versamune&#xAE; HPV (PDS0101) studies that were presented during the Head and Neck Cancer Poster Session taking place May 30-June 3, 2025, in Chicago, Illinois.
It is estimated that over 50% of head and neck squamous cell carcinoma (HNSCC) cases in the US are HPV16-positive.1 HPV-positive and HPV-negative HNSCC are two distinct diseases with different underlying causes, origin, risk factors, and contributions to the development of HNSCC. Multiple types of HPV are associated with HSNCC, and those cases are commonly identified with a p16 histochemistry test and referred to as p16-positive. A p16-positive test result suggests that the patient's cancer may be due to any of the over 100 types of HPV. PDS Biotech is specifically addressing HNSCC related to HPV type 16 (HPV16), the most carcinogenic type of HPV. 2 HPV16-positive HNSCC has been identified as a rapidly growing and severe medical need.3,4 HPV16 is a specific type of HPV that must be confirmed using a polymerase chain reaction (PCR) test.

Biotech

General

PDSB

PDS Biotech Reports Durable 30-Month Median Overall Survival In 1L Recurrent/Metastatic HNSCC, Highlights Urgent Need In Rapidly Rising HPV16-Positive Cases

<ul>
<li>Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo &nbsp;</li>
<li>Phase 3 study showed patient-reported functional benefit in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision, a condition with no current FDA-approved therapies &nbsp;</li>
<li>Safety profile consistent with previous studies, with no new safety signals identified&nbsp; &nbsp;</li>
<li>No evidence of tachyphylaxis was observed in this study over the 6-week period &nbsp;</li>
<li>Study was conducted under FDA Special Protocol Assessment and Fast-Track Designation &nbsp;</li>
</ul>

Opus Genetics; LYNX-2 Phase 3 Trial Met Primary Endpoint For Phentolamine Ophthalmic Solution 0.75% In Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Management

STRO

Sutro Biopharma Appoints Greg Chow As CFO, Effective June 2, 2025

NMAX

Newsmax Expects To List On U.S. Small-Cap Russell 2000 Index, Effective June 30, 2025, As Part Of 2025 Russell Indexes Reconstitution

Indaptus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announces that the first patient has been dosed in the expansion arm of its Phase 1b/2 clinical trial evaluating Decoy20 in combination with BeOne's (formerly known as Beigene) PD-1 checkpoint inhibitor, tislelizumab. This newly activated arm of the trial will assess safety, dose optimization, and early signs of anti-tumor activity in patients with advanced solid tumors, previously treated with a checkpoint inhibitor or with tumors typically unresponsive to a checkpoint inhibitor.

INDP

Indaptus Therapeutics Doses First Patient In Phase 1b/2 Trial Expansion Of Decoy20 Combo For Advanced Solid Tumors

<h3>Gainers</h3>
<ul>
<li>Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) shares increased by 26.1% to $7.35 during Monday's pre-market session. The market value of their outstanding shares is at $3.6 billion. </li>
<li>Century Aluminum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENX#NASDAQ">CENX</a>) shares rose 18.85% to $18.41. The market value of their outstanding shares is at $1.7 billion. </li>
<li>Steel Dynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) stock moved upwards by 11.31% to $137.0. The market value of their outstanding shares is at $20.3 billion. </li>
<li>Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) stock moved upwards by 10.74% to $121.11. The company's market cap stands at $27.9 billion. </li>
<li>Origin Materials (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGN#NASDAQ">ORGN</a>) stock moved upwards by 9.25% to $0.48. The company's market cap stands at $71.6 million. </li>
<li>Commercial Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) shares moved upwards by 9.2% to $50.88. The market value of their outstanding shares is at $5.7 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bolt Projects Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSLK#NASDAQ">BSLK</a>) shares declined by 8.3% to $3.1 during Monday's pre-market session. The company's market cap stands at $6.3 million. </li>
<li>IT Tech Packaging (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITP#AMEX">ITP</a>) shares decreased by 6.85% to $0.18. The market value of their outstanding shares is at $3.0 million. </li>
<li>IperionX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPX#NASDAQ">IPX</a>) stock decreased by 6.5% to $22.62. The market value of their outstanding shares is at $662.0 million. </li>
<li>Millennium Group Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGIH#NASDAQ">MGIH</a>) stock fell 6.05% to $1.4. The company's market cap stands at $15.7 million. </li>
<li>Tantech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TANH#NASDAQ">TANH</a>) stock declined by 5.41% to $2.1. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-basic-materials-stocks/" title="www.benzinga.com/money/best-basic-materials-stocks/">www.benzinga.com/money/best-basic-materials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSLK

CENX

MGIH

ORGN

STLD

TANH

11 Materials Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Educational Development (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDUC#NASDAQ">EDUC</a>) stock increased by 53.7% to $2.09 during Monday's pre-market session. The market value of their outstanding shares is at $17.9 million. </li>
<li>Mixed Martial Arts Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) stock increased by 10.11% to $0.98. The company's market cap stands at $10.2 million. </li>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) stock increased by 9.99% to $0.35. The company's market cap stands at $24.7 million. </li>
<li>United Homes Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) shares increased by 7.61% to $3.25. The market value of their outstanding shares is at $190.4 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) stock increased by 7.59% to $2.11. The company's market cap stands at $9.9 million. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSA#NASDAQ">VSA</a>) shares increased by 7.59% to $0.85. The market value of their outstanding shares is at $8.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>China Liberal Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) stock decreased by 28.3% to $0.7 during Monday's pre-market session. The market value of their outstanding shares is at $188.1 million. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) shares declined by 21.11% to $60.51. The company's market cap stands at $42.2 million. </li>
<li>ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) shares fell 18.42% to $6.69. The company's market cap stands at $178.5 million. </li>
<li>ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) stock declined by 14.49% to $0.29. The company's market cap stands at $10.3 million. </li>
<li>Envela (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELA#AMEX">ELA</a>) stock declined by 13.8% to $5.0. The market value of their outstanding shares is at $129.9 million. </li>
<li>High Roller Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ROLR#AMEX">ROLR</a>) shares decreased by 11.47% to $3.86. The market value of their outstanding shares is at $32.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLEU

ECDA

EDUC

LOGC

ROLR

SBET

12 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares moved upwards by 463.3% to $27.77 during Monday's pre-market session. The market value of their outstanding shares is at $36.8 million. </li>
<li>Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) shares increased by 62.58% to $30.81. The company's market cap stands at $1.9 billion. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock increased by 39.8% to $0.4. The company's market cap stands at $2.3 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) stock increased by 39.09% to $8.46. The market value of their outstanding shares is at $158.8 million. </li>
<li>Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) stock rose 34.95% to $40.0. The company's market cap stands at $2.6 billion. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) shares moved upwards by 30.9% to $35.28. The company's market cap stands at $231.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Telomir Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) stock declined by 24.9% to $1.46 during Monday's pre-market session. The company's market cap stands at $43.4 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock decreased by 21.98% to $0.83. The company's market cap stands at $43.2 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares fell 19.27% to $3.96. The market value of their outstanding shares is at $2.9 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock fell 16.21% to $0.87. The company's market cap stands at $7.5 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock fell 12.21% to $770.0. The market value of their outstanding shares is at $10.0 billion. </li>
<li>Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) shares fell 10.8% to $1.24. The company's market cap stands at $125.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMGL

KYMR

LUCD

LYRA

PSTV

RSLS

SLXN

TELO

VERA

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Webus International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETO#NASDAQ">WETO</a>) stock moved upwards by 91.7% to $5.56 during Monday's pre-market session. The market value of their outstanding shares is at $122.3 million. </li>
<li>Armlogi Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOC#NASDAQ">BTOC</a>) shares rose 17.43% to $1.28. The market value of their outstanding shares is at $53.9 million. </li>
<li>Arrive AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAI#NASDAQ">ARAI</a>) shares increased by 14.89% to $6.71. The market value of their outstanding shares is at $201.1 million. </li>
<li>Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) stock increased by 13.11% to $1.38. The company's market cap stands at $5.1 million. </li>
<li>Captivision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPT#NASDAQ">CAPT</a>) stock moved upwards by 12.84% to $1.23. The market value of their outstanding shares is at $40.1 million. </li>
<li>Hong Kong Pharma Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKPD#NASDAQ">HKPD</a>) shares increased by 12.82% to $1.32. The market value of their outstanding shares is at $14.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nuburu (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BURU#AMEX">BURU</a>) shares decreased by 13.1% to $0.32 during Monday's pre-market session. The company's market cap stands at $16.7 million. </li>
<li>ESS Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) shares decreased by 9.42% to $1.54. The market value of their outstanding shares is at $18.6 million. </li>
<li>New Horizon Aircraft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) shares declined by 6.61% to $0.99. The company's market cap stands at $31.0 million. </li>
<li>Quhuo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QH#NASDAQ">QH</a>) stock decreased by 6.56% to $1.14. The company's market cap stands at $102.2 million. </li>
<li>Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) shares fell 6.53% to $108.0. The company's market cap stands at $5.0 billion. As per the press release, Q1 earnings came out today. </li>
<li>Complete Solaria (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) shares declined by 6.48% to $1.3. The market value of their outstanding shares is at $104.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARAI

BTOC

BURU

CAPT

HKPD

HOVR

NVVE

SAIC

SPWR

WETO

12 Industrials Stocks Moving In Monday's Pre-Market Session

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Wheeler Real Estate Investment Trust Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)</h3>
<ul class="wp-block-list">
<li>On May 22, Wheeler Real Estate Investment Trust announced it will implement a 1-for-7 reverse stock split. The company's stock fell around 89% over the past five days and has a 52-week low of $3.92.</li>
<li>RSI Value: 29.4</li>
<li>WHLR Price Action: Shares of Wheeler Real Estate Investment Trust fell 8.3% to close at $3.98 on Friday.</li>
<li>Edge Stock Ratings: Value at 41.34. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/whlr"><img loading="lazy" decoding="async" width="497" height="182" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02080420/image-3.png" alt="" class="wp-image-935058" style="width:410px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02080420/image-3.png 497w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02080420/image-3-300x110.png 300w" sizes="(max-width: 497px) 100vw, 497px" /></a></figure>
<h3 class="wp-block-heading">Office Properties Income Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPI#NASDAQ">OPI</a>)</h3>
<ul class="wp-block-list">
<li>On April 30, Office Props IT posted downbeat quarterly earnings. The company's stock fell around 40% over the past month and <a href="https://www.benzinga.com/quote/OPI">has a 52-week low</a> of $0.18.</li>
<li>RSI Value: 27.7</li>
<li>OPI Price Action: Shares of Office Properties Income Trust fell 8.1% to close at $0.19 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in OPI stock. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0602"><img loading="lazy" decoding="async" width="932" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02080531/image-4.png" alt="" class="wp-image-935060" style="width:714px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02080531/image-4.png 932w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02080531/image-4-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02080531/image-4-768x698.png 768w" sizes="(max-width: 932px) 100vw, 932px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Trading Ideas

WHLR

Top 2 Real Estate Stocks That Could Surge This Quarter

Lineage, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) (the "Company"), the world's largest global temperature-controlled warehouse REIT, today announces the planned retirement of its Chief Financial Officer, Rob Crisci. The Company has started the process of identifying a successor for the position with the assistance of a leading executive search firm. Crisci will continue as CFO until a successor is in place and will remain with Lineage through a subsequent transition period.
 &nbsp;

LINE

Lineage Announces Planned Retirement Of CFO, Rob Crisci

Progress continues on the development of AVERSA Fentanyl, with the Company formalizing an exclusive product development partnership with Kindeva Drug Delivery. The formalized partnership with Kindeva Drug Delivery reflects a commitment to shared development costs in exchange for milestone payments, enabling Nutriband to advance its innovative transdermal drug delivery solutions towards regulatory approval and commercialization.
AVERSA Fentanyl has the potential to be the world's first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA Fentanyl has the potential to reach peak annual US sales of $80 million to $200 million.1
1&nbsp;Health Advances Aversa Fentanyl market analysis report 2022

Earnings

NTRB

Nutriband Quarterly Reports Revenue For Q1 2025, Up 63% YOY And Announces Strategic Progress Toward NDA Filing For Abuse-Deterrent Patch Development Of AVERSA Fentanyl

Most people have heard the saying "better late than never," but it has an entirely different meaning when you're 50 years old and have no money saved up for retirement. It's a difficult situation, but it doesn't have to be the end of the world.<a href="https://www.gobankingrates.com/retirement/planning/50-with-no-retirement-savings-how-i-retired-comfortably/"> GOBankingRates</a> recently profiled an investor who got themselves out of this unenviable situation by committing to lifestyle changes, ambition, and astute planning.
Admitting you have a problem is the first step to getting out of any difficult situation. Once that's done, the next step is making a plan. That's exactly what Jennifer James did when she realized she was dangerously close to retirement age with inadequate savings. Saving money sounds like it's easy, but it can be challenging when your employment income doesn't leave you with enough discretionary funds to stash any away for a rainy day.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>
That's why James' first step was improving on their $45,000 per year salary. "I knew I had to increase my income, but without a college degree, I felt stuck. I was living paycheck to paycheck just trying to get by," James told GOBankingRates. She followed the advice of several confidants by returning to school to earn her bachelor's degree. It was a struggle, but the payoff was worth it.
Getting her bachelor's degree allowed James to secure a job as an office manager and boosted her annual salary to $65,000.&nbsp; "Finally finishing my degree opened up new opportunities that changed everything," she said. "It was a struggle, but well worth the effort." By that point, James was 53, but she had the discipline to begin putting her extra income to work for her.
James told GOBankingRates that she began saving 20% of her take-home pay, a move that allowed her to stockpile investment capital and build an emergency fund. "I set up automatic transfers from my checking account to savings so I paid myself first," James said. She admitted living on such a tight budget was a challenge, but the reward made all the sacrifices worthwhile.
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.
According to GOBankingRates, James' next step was to make up for lost time by maximizing her 401(k) contribution, which was 15% of her pre-tax income. James was also eligible to make catch-up contributions to the 401(k) plan because she was over 50, and she exercised that option. Her employer also matched 50% of her contributions, which helped James grow her nest egg even more quickly.
&nbsp;If that wasn't enough, James also opened an<a href="https://www.benzinga.com/money/best-ira-accounts"> IRA</a> and committed to making the maximum allowable annual contribution. GOBankingRates revealed that James had saved $100,000 by the time she was 58 and felt confident enough to take the next step to wealth building: buying a house. She used her savings to put 30% down and then made bi-weekly mortgage payments before paying the loan off within eight years.
By the time James turned 60, she felt like she was ready to take the final step in building her retirement package: developing a stock portfolio. She applied the same discipline she used in getting her bachelor's degree and learned about the market. "I focused on adding money to a mix of strong<a href="https://www.benzinga.com/money/best-dividend-stocks-to-buy-and-hold"> dividend stocks</a> and low-cost index funds," James told GOBankingRates. "Dollar-cost averaging helped minimize the normal ups and downs of the market."&nbsp;&nbsp;
See Also: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
James retired from her full-time job at 65 and transitioned to a part-time job that provides her with a little extra spending money. Some might call it a miraculous turnaround, but that wouldn't be giving James enough credit. It took discipline, planning, and commitment to reach her goals, and she couldn't be happier.&nbsp; She looks back on her self-motivated transition from financial crisis to a comfortable retirement with pride.
"The key was cutting spending to maximize savings once my income increased. I'm now 68 and loving early retirement," James said. "It just goes to show, it's never too late to turn your financial life around if you focus and work a plan."
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
Image: Shutterstock

Personal Finance

How This Investor Went From Being 50 Years Old With No Savings To A Comfortable Retirement At 65

LMP Capital and Income Fund Board Approves 1-For-3 Rights Offering

Dr. Mehmet Oz, appointed by President Donald Trump to lead the Centers for Medicare and Medicaid Services (CMS), added to the chorus of Republican voices defending the funding cuts in the House-passed budget bill.
What Happened: Speaking <a href="https://www.youtube.com/watch?v=1GjUYBLYTyU">on</a> POLITICO's podcast The Conversation with Dasha Burns, Oz said the proposed eligibility requirements are not about withdrawing care but about making sure the program survives long-term. "I'm trying to save Medicaid," Oz said. "That's the president's goal as well. He said over and over again, he wants to love and cherish these programs and we need to keep them viable."
Oz added: "Every great people takes care of their most vulnerable, and we're a great nation." "We're gonna do that."
"There is no proposal I've seen, in fact, in fairness, that doesn't increase spending on Medicaid," he said.
See Also: <a href="https://www.benzinga.com/cannabis/25/06/45718360/jony-ive-once-said-steve-jobs-demanded-everyone-at-apple-often-answer-this-question-it-still-shocks-me-how-few-people-actually-practice-this">Jony Ive Once Said Steve Jobs Demanded Everyone At Apple Often Answer This Question: &#8216;It Still Shocks Me How Few People Actually Practice This&#8217;</a>
Why It Matters: The Congressional Budget Office projects that the new provisions are likely to save $625 billion of the targeted $800 billion in savings over the next ten years. In April, Trump said he would <a href="https://www.benzinga.com/government/25/04/45064937/donald-trump-threatens-to-veto-any-gop-bill-that-touches-medicaid-or-social-security-if-it-cuts-it-i-would-not-approve">"veto" any bill that includes cuts to Medicaid</a>. However, as the bill progressed, Medicaid cuts became central to its project of reducing federal spending, and <a href="https://www.benzinga.com/general/health-care/25/05/45345409/trumps-big-beautiful-bill-banks-on-huge-medicaid-cuts-as-its-cost-saving-centerpiece-see-who-risks-losing-coverage-under-the-gop-proposal">millions are set to lose coverage</a>.
Trump&#8217;s crypto and AI advisor,&nbsp;David Sacks, acknowledged that the&nbsp;<a href="https://www.benzinga.com/25/05/45582778/trumps-big-beautiful-bill-passes-house-what-it-means-for-taxes-student-loans-medicaid-and-more" target="_blank" rel="noreferrer noopener"> bill</a>&nbsp;"cuts <a href="https://www.benzinga.com/general/health-care/25/05/45616625/trump-advisor-david-sacks-admits-new-bill-cuts-880-billion-from-medicaid-as-speaker-mike-johnson-insists-we-have-not-cut-medicaid-and-trump-says-working-class-wont-lose-health-insurance">$880 billion from Medicaid</a> over a decade.&#8221; However, Office of Management and Budget Director Russell Vought <a href="https://www.benzinga.com/news/politics/25/06/45717492/medicaid-cut-concerns-are-totally-ridiculous-says-trumps-budget-chief-russell-vought-quips-i-love-elon-while-countering-musks-criticism">dismissed fears about Medicaid cuts</a> as "ridiculous," and Speaker Mike Johnson (R-La.) argued that <a href="https://www.benzinga.com/news/politics/25/06/45716936/speaker-mike-johnson-says-4-8-million-wont-lose-medicaid-unless-they-choose-to-do-so-calls-gop-cuts-an-important-and-frankly-heroic-thing">those who lose Medicaid</a> under the bill will do so by personal choice.
Sen. Joni Ernst (R-Iowa) brushed off a voter&#8217;s warning about the effects of losing healthcare by replying, <a href="https://www.benzinga.com/news/politics/25/06/45718265/medicaid-cuts-backlash-grows-as-sen-joni-ernst-tells-voters-well-we-all-are-going-to-die-mocks-critics-from-a-cemetery">&#8220;Well, we all are going to die.&#8221;</a> On the other hand, Sen. Josh Hawley (R-Mo.) wrote in an op-ed that the Republican party is facing an "identity crisis" and that Medicaid cuts are <a href="https://www.benzinga.com/25/05/45369487/josh-hawley-slams-gop-identity-crisis-over-medicaid-calls-proposed-cuts-morally-wrong-and-politically-suicidal">"morally wrong and politically suicidal."</a>
Read Next: <a href="https://www.benzinga.com/news/politics/25/06/45718255/elizabeth-warren-agrees-with-trump-on-scrapping-debt-limit-but-blasts-4-trillion-hike-for-billionaire-tax-breaks">Elizabeth Warren Agrees With Trump On Scrapping Debt Limit—But Blasts $4 Trillion Hike For Billionaire Tax Breaks</a>
Image Via Shutterstock/IB Photography

Health Care

Politics

'I'm Trying To Save Medicaid,' Says Trump-Appointed CMS Chief Dr. Oz As CBO Estimates 7.6 Million Could Lose Coverage Under GOP's 'Big, Beautiful Bill'

Truist Securities analyst Matthew Coad initiates coverage on Global Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) with a Hold rating and announces Price Target of $79.

Price Target

Initiation

Analyst Ratings

Truist Securities Initiates Coverage On Global Payments with Hold Rating, Announces Price Target of $79

Highlights the unique potential of Celularity's proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstruction Supports broad range of regenerative medicine applications beyond ophthalmology
FLORHAM PARK, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced its research published in the May 29, 2025, issue of the peer-reviewed journal <a href="https://www.globenewswire.com/Tracker?data=vDISEZEY74ZiTLdYu0e6sRfpcUrhD_2MQ4t29LIWl-cv4Jx2-ZwsywwDKuOMtokaLWY5NFbudBiXVnkptKTn4ru13KPyXTyXlUOZyUl0HA6gtLZAE2Vy9u6GsGr8AhRE1tTMacS6ZofIFATGOFD69zSKap3Ugogk1Eq7D8qN0JU86dDxOWeYZCnOiL50Aw1d">Regenerative Engineering and Translational Medicine</a>, a leading open-access journal publishing cutting-edge advances in regenerative medicine.
The full study titled "Tri-Layer Decellularized, Dehydrated Amniotic Membrane Supports Proliferation and Stemness of Limbal Stem Cells Derived from Pluripotent Stem Cells" demonstrates the potential of Celularity's proprietary tri-layer decellularized, dehydrated human amniotic membrane (DDHAM-3L) as an innovative carrier for induced pluripotent stem cell (iPSC)-derived limbal stem cells (LSCs) in treating limbal stem cell deficiency (LSCD) and other ocular surface disorders.
The research conducted in collaboration with Dr. Jessica M. Gluck's team at North Carolina State University (NCSU) highlights DDHAM-3L's ability to support the adhesion, proliferation, and stemness of iPSC-derived LSCs. "Our work unlocks a scalable, off-the-shelf solution for ocular surface reconstruction," said&nbsp;Dr. Jessica M. Gluck, senior author of the study. "DDHAM-3L demonstrates its biocompatibility with LSCs and future utilization in the clinic." Over a 7-day in vitro study, iPSC-LSCs seeded on DDHAM-3L formed confluent cell sheets, exhibited epithelial morphology, and demonstrated a higher proliferation rate compared to controls. Gene and protein expression analyses further confirmed the upregulation of markers associated with stemness, self-renewal, and corneal epithelial commitment, underscoring DDHAM-3L's potential as an advanced biomaterial for ocular surface reconstruction.

CELU

Celularity Highlights Unique Potential Of Proprietary Advanced Biomaterial Technology As Novel Cellular Delivery System For Ocular Surface Reconstruction

Truist Securities analyst Matthew Coad initiates coverage on Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) with a Hold rating and announces Price Target of $84.

Truist Securities Initiates Coverage On Fidelity National Info with Hold Rating, Announces Price Target of $84

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the first patient has been enrolled in its new Phase 2 clinical trial protocol of stenoparib for the treatment of advanced, platinum-resistant or platinum-ineligible ovarian cancer.
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP&#xAE;) companion diagnostic (CDx) toward potential FDA approval. It builds on encouraging data from Allarity's earlier and still ongoing Phase 2 study, which demonstrated that patients on twice-daily stenoparib showed durable clinical benefit and that stenoparib was well tolerated. Two patients remain on treatment and continue to derive benefit after more than 20 months. Reflecting the compelling and durable clinical responses observed in platinum-resistant patients to date, the new trial protocol specifically focuses on evaluating stenoparib in patients with advanced, recurrent, platinum-resistant, or platinum-ineligible ovarian cancer—patients for whom current treatment options are extremely limited and typically involve additional chemotherapy, which is associated with well-documented side effects.

ALLR

Allarity Therapeutics Says First Patient Enrolled In New Phase 2 Clinical Trial Protocol Of Stenoparib For Treatment Of Advanced, Platinum-Resistant Or Platinum-Ineligible Ovarian Cancer

Press Releases

Bluejay Diagnostics Announces Reverse Stock Split

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering

Financing

Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering

Bitech Technologies (OTCQB: BTTC) Appoints Montgomery Bannerman to Drive Strategic Growth in Renewable Energy – see other stocks inside….

Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds

Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting

Comments

Bluejay Diagnostics

Bluejay Diagnostics (BJDX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL